combination treatment, though the difference was not statistically significant.
As any one cytotoxic drug appears to be effective in little more than 60 % of cases and as the duration of response, where this can be demonstrated clinically, tends to be so short, it seems that a combination of three or more drugs administered over a relatively long period of time, similar to the combined treatment used by Carbone, should be employed to give the best prospect of demonstrating any effect in long-term survival rate. However, such a course of treatment is bound to be exhausting to the patient and is not without risk, so one is hesitant to set up such a trial where as many as 500% of the patients would be potential long-term survivors. Probably one should wait until combination regimes have been more fully assessed in patients in the later stages of the disease before using them in the early cases. One also hopes for the introduction of more potent drugs.
The position in Hodgkin's disease is also found in the other lymphomas with the proviso that, on the whole, chemotherapy tends to be rather less effective and there is often a less varied range of agents from which to choose. An outstanding exception, of course, is Burkitt's lymphoma in which chemotherapy is sometimes curative. Even in this condition, it is disappointing to find that in a recent symposium published in the International Journal of Cancer (1967) longterm survival has very rarely been seen outside Africa.
In conclusion, one can say that there is now a range of drugs, including several alkylating agents, corticosteroids, vinca alkaloids and procarbazine which may be regarded as standard agents in the treatment of Hodgkin's disease and that current interest centres on the possible advantage of combining several of these drugs together.
Mr G Westbury (Westminster Hospital, London)
Chemotherapy of Malignant Melanoma
Systemic Administration For practical purposes the chemotherapy of malignant melanoma means regional intraarterial chemotherapy. Our experience at Westminster Hospital with a wide range of cytotoxic agents, given systemically either singly or in combination, has been disappointing. The rare example of improvement is to be regarded as something of a freak response and in general treatment simply adds to the patient's burden. Ariel & Pack (1967) reported improvement in disseminated disease with a triple regime of systemic melphalan, methotrexate and autogenous bone marrow transplants, describing subjective and objective improvement although at the expense of morbidity and a small mortality. Westbury et al. (1959) reported preliminary observations on massive dose chemotherapy with mannomustine and bone marrow transplantation. They observed dramatic but transient response of skin nodules but noted in this and later cases the hazard of cerebral hkmorrhage from necrosis of metastases, no doubt aggravated by reduction of the blood platelets. In this respect it is interesting that Beresford (1968) found cerebral involvement in 44% of patients with widespread melanoma who came to autopsy.
Chemotherapy and Irradiation
Malignant melanoma is generally held to be a radio-resistant disease though Lederman (1961) has pointed out that this is not true for all sites. The effects of irradiation are potentiated by certain cytotoxic drugs and this combination has been tested in melanoma by Dr Kenneth Newton using vinblastine intravenously. So far, more than half the patients, in a small series, have responded to a degree graded as excellent.
Regional Intra-arterial Chemotherapy Regional intra-arterial therapy was first described in 1950 by Klopp and his colleagues, who produced regression of epithelial tumours, hitherto not achieved by cytotoxic agents. From their original simple intra-arterial injection has stemmed a variety of technical modifications designed to permit higher regional dosage while reducing systemic toxicity from spill-over.
Extracorporeal perfusion: Creech and his colleagues, in 1958, demonstrated the value of isolated extracorporeal perfusion for malignant melanoma. The perfusion technique can be applied to many parts of the body but its most obvious use is in the limbs. For perfusion of the entire limb, including the inguinal or axillary node regions, cannulation of the iliac or subclavian vessels respectively is required and at these levels the application of an efficient proximal tourniquet is difficult. We now therefore restrict extracorporeal perfusion to lesions of the distal portions of the limbs where tourniquet isolation can be virtually complete and, incidentally, the surgical procedure relatively minor. For treatment of the limb root, our own practice is to use simpler infusion techniques as described below.
Fifty perfusions have been performed in 48 patients over the last nine years. Melphalan has been used in most cases. Perfusion led to the loss of a limb in one patient as the result of too high a perfusion temperature. Of 36 perfusions suitable for evaluation, complete clinical remission was achieved in 9 patients, partial remission in 21 and no remission in 6. Stehlin & Clark (1965) have suggested that in addition to the palliative value of perfusion this procedure, when added to the standard surgical excision of early melanoma, may produce as much as a 10% improvement in survival rates. The excellent figures obtained in favourable groups by surgeons such as Bodenham (1968) suggest, however, that there is no good case for adding perfusion to surgery as a routine. In our view the indiscriminate addition of perfusion in such cases adds an unwarrantable and often unnecessary morbidity and prolongation of hospital stay.
Intra-arterial infusion: Where disease has involved the limb root we have tried to simplify the regional chemotherapy of malignant melanoma by the use of infusion techniques. The femoral artery is cannulated by Seldinger needle puncture or sometimes retirograde passage of a specially long catheter via the dorsalis pedis or posterior tibial artery. The latter method is preferred where possible but difficulty is sometimes met in negotiating the popliteal bifurcation, especially in the elderly. In the upper limb retrograde cannulation via the radial artery has been consistently successful and safe. The position of the catheter tip is checked with fluorescein. The entire hind or forequarter is readily covered.
Of the various cytotoxic drugs tested the most satisfactory of all has been the podophyllin derivative, mitopodozide (Newton et al. 1964) . In well over 100 infusions of this drug for all diseases and in various sites, often to the limit of tissue tolerance, no single example of white cell depression from spill-over has been observed.
In spite of occasional arterial thrombosis at the puncture site no limbs have been lost following 85 infusions in 78 patients. Of 49 cases suitable for evaluation, complete clinical response was achieved in 4, partial in 30, and no response in 15.
Conclusions
In malignant melanoma systemic chemotherapy has practically no place in the management of the disseminated disease.
The use of cytotoxic agents as radio-potentiators is promising and should be considered for the palliation of locally troublesome deposits.
Regional infusion and perfusion have proved to be helpful in the control of locally advanced or recurrent disease in the limbs, either alone or in combination with limited surgical procedures. We do not now consider that these techniques should be used routinely to supplement standard excisional surgery in the locally favourable case as the morbidity and additional hospital stay are not likely to be accompanied by worth-while benefit.
